Plus Therapeutics (PSTV) has closed a private placement with aggregate initial upfront proceeds of approximately $3.7 million and received a ...

Recently we had a conversation with Shardule Shah, CEO and founder of Lime Therapeutics, a company dedicated to advancing therapies for diseases related to dysfunctional lipid metabolism. By ...

Million Private Placement Financing from Existing Investors$2.0 Million Funding Advance from the Cancer Prevention and Research Institute of ...

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological ...

TransCode Therapeutics (RNAZ) shares are rising after dosing the first patient in Cohort 3 of its Phase 1 trial for lead candidate TTX-MC138 No significant safety issues were reported in previous ...

TG Therapeutics, Inc. (NASDAQ:TGTX) presented at the JP Morgan Healthcare Conference last week and CEO Michael Weiss used the time to talk about the accomplishments in 2024 and to provide fresh ...

Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze ...